Long-term oncologic outcomes of laparoscopic nephroureterectomy versus open nephroureterectomy for upper tract urothelial carcinoma: a systematic review and meta-analysis

Su Zhang*, You Luo*, Cheng Wang*, Sheng-Jun Fu and Li Yang
Department of Urology, Lanzhou University Second Hospital, Lan Zhou, China
*These authors contributed equally to this work.

ABSTRACT

Background. Several factors have been validated as predictors of disease recurrence in upper tract urothelial carcinoma. However, the oncological outcomes between different surgical approaches (open nephroureterectomy versus laparoscopic nephroureterectomy, ONU vs LNU) remain controversial. Therefore, we performed a meta-analysis to evaluate the oncological outcomes associated with different surgical approaches.

Methods. We conducted an electronic search of the PubMed, Embase, ISI Web of Knowledge and Cochrane Library electronic databases through November 2015, screened the retrieved references, collected and evaluated the relevant information. We extracted and synthesized the corresponding hazard ratios (HRs) and 95% confidence intervals (95% CI) using Stata 13.

Results. Twenty-one observational studies were eligible for inclusion in the meta-analysis. The results of the meta-analysis showed no differences in the intravesical recurrence-free survival (IRFS), unspecified recurrence-free survival (UnRFS) and overall survival (OS) between LNU and ONU. However, improvements in the extravesical recurrence free survival (ExRFS) and cancer specific survival (CSS) were observed in LNU. The pooled hazard ratios were 1.05 (95% CI [0.92–1.18]) for IRFS, 0.80 (95% CI [0.64–0.96]) for ExRFS, 1.10 (95% CI [0.93–1.28]) for UnRFS, 0.91 (95% CI [0.66–1.17]) for OS and 0.79 (95% CI [0.68–0.91]) for CSS.

Conclusion. Based on current evidence, LNU could provide equivalent prognostic effects for upper tract urothelial carcinoma, and had better oncological control of ExRFS and CSS compared to ONU. However, considering all eligible studies with the intrinsic bias of retrospective study design, the results should be interpreted with caution. Prospective randomized trials are needed to verify these results.

INTRODUCTION

Upper tract urothelial carcinoma (UTUC), accounting for only 5% of all urothelial cancers, is a rare malignancy with high risk for disease recurrence and mortality (Roupret et al., 2015). Given its high potential for recurrence and poor prognosis, assessment of
the predictive factors appears to be increasingly significant. Tumor multifocality, previous bladder cancer and concomitant carcinoma in situ (CIS) have been validated as predictors of intravesical recurrence, which is also associated with different surgical approaches (Xylinas et al., 2013; Xylinas et al., 2014). The standard treatment for UTUC is nephroureterectomy with bladder cuff excision. The treatment approaches include open nephroureterectomy (ONU) and laparoscopic nephroureterectomy (LNU). Compared with ONU, a traditional approach which has durable oncologic control, LNU has shown several advantages with fewer adverse intra- and perioperative outcomes as a minimally invasive treatment since being first introduced by Clayman in 1991 (Clayman et al., 1991; Simone et al., 2009). However, compared to ONU, whether LNU has equivalent oncological outcomes, such as cancer-specific survival (CSS) and intravesical recurrence-free survival (IRFS), remains controversial (Kim et al., 2015; Xylinas et al., 2014). We aimed to perform a meta-analysis to evaluate the oncological control associated with different surgical approaches (ONU vs LNU).

**METHODS**

**Search and screen strategy**

A systematic literature search of Embase, PubMed, ISI Web of Knowledge and Cochrane Library was conducted to retrieve UTUC studies comprising both surgical approaches (ONU and LNU) through November 1, 2015. The search key words included open nephroureterectomy, laparoscopic nephroureterectomy, upper tract urothelial carcinoma, and others. The detailed search strategy is presented in Supplemental Information 2. We also screened the citations in the retrieved articles for any relevant studies. Two independent investigators (S Zhang and Y Luo) conducted the initial screening by reviewing the title and abstract. Then, the full-text articles satisfying the inclusion criteria were reviewed. Clinical studies recording any evaluation of the surgical approach on oncological outcomes, including intravesical recurrence-free survival (IRFS), extravesical recurrence-free survival (ExRFS), unspecified recurrence-free survival (UnRFS, reported as disease recurrence but not explicitly defined as IRFS or ExRFS), cancer-specific survival (CSS) or overall survival (OS), were eligible. Articles were excluded if they met any of the following criteria: (1) the aforementioned outcomes were not described; (2) patients were treated by hand assisted laparoscopic nephroureterectomy; or (3) studies included overlapping patients or duplicated data. Instead, the study with the largest sample size would be selected if more than one study included overlapping patients. This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) (Moher et al., 2010). Ethical approval and patient consent were waived because all available data were extracted from previous publications.

**Data extraction and assessment of methodological quality**

The basic information including first author, year of publication, region, recruitment period, number of patients who underwent LNU or ONU, age of patients, follow-up, oncological outcomes, and adjusted factors were extracted by two researchers (S Zhang and Y Luo) independently. Any disagreement or uncertainty was determined by group
discussion, and a consensus was obtained. The data were extracted from the original articles. For incomplete data, we attempted to contact the corresponding author to acquire primary data. During data extraction, multivariate outcomes rather than univariate outcomes were preferred when both results were provided. If multivariate results were not available, univariate outcomes were an alternative to conduct this analysis. Publication bias and sensitivity analyses were applied. The quality assessments of cohort studies were conducted according to the Newcastle-Ottawa Scale (NOS), which was developed to assess bias risk including three domains with eight items. Five or more stars out of a total of nine stars was regarded as good quality (Wells et al., 2008).

Statistical analysis
All data and analysis were conducted using STATA 13 software (Stata Corp LP, College Station, TX, USA). The survival outcomes were evaluated by hazard ratios (HR) and 95% confident intervals. $I^2$ statistics and the chi-square test were calculated for heterogeneity detection. When $P \geq 0.1$ and $I^2 \leq 50\%$, a fixed-effects model was performed; otherwise, a random effects model was applied. An inverse variance method was used to calculate the pooled hazard ratio. Sensitivity analyses were conducted to test the stability of the pooled results. Egger’s test for publication bias was performed only in outcomes that enrolled more than ten studies (Egger et al., 1997). Additionally, we conducted subgroup and multivariable meta-regression in IRFS according to the different approach of LNU (retroperitoneal vs. transperitoneal), sample size of LNU (<100 vs $\geq 100$) and publication year. A $P$ value of less than 0.05 was deemed statistically significant.

RESULTS
Description of included studies
In total, 1,506 citations were retrieved by the initial search strategy. After three rounds of screening, there were 21 cohort studies for quantitative synthesis. The PRISMA flow diagram is presented in Fig. 1. Table 1 shows the detailed characteristics of the included studies. The Newcastle Ottawa Scale (NOS) assessment showed that all included cohort studies had relatively well controlled quality.

Survival outcomes
Oncological recurrence
The IRFS was reported in thirteen articles, which included LNU ($n = 1,959$) and ONU ($n = 4,281$) (Favaretto et al., 2010; Fradet et al., 2014; Ishikawa et al., 2010; Ito et al., 2013; Kim et al., 2015; Kitamura et al., 2014; Kobayashi et al., 2012; Koda et al., 2007; Kume et al., 2006; Ploussard et al., 2015; Terakawa et al., 2008; Xylinas et al., 2013; Zou et al., 2014). The meta-analysis results showed no significant difference in the IRFS between LNU and ONU management (HR 1.05, 95% CI [0.92–1.18]; $P = 0.134$, $I^2 = 31.1\%$; Fig. 2). The ExRFS was described in four studies including patients who underwent LNU ($n = 836$) and ONU ($n = 4,315$) (Capitanio et al., 2009; Rieken et al., 2014; Walton et al., 2011; Yafi et al., 2012). The pooled results showed that LNU management decreased the risk of extravesical recurrence (HR 0.80, 95% CI [0.64–0.96]; $P = 0.859$, $I^2 = 0.0\%$; Fig. 3). Five
| Study                  | Country     | Duration        | N of pts (ONU/LNU) | Age (yrs) (ONU/LNU) | Follow up (month) (ONU/ LNU) | Outcomes           | Approach of LNU | NOS | Adjusted factors             |
|-----------------------|-------------|-----------------|--------------------|--------------------|-----------------------------|--------------------|-----------------|-----|------------------------------|
| Favaretto et al. (2010) | USA         | 2002–2008       | 109/53             | Md73 (IQR67-78) Md71 (IQR64-76) | Md23                     | UnRFS, IRFS       | Mixed          | 6   | Age, ASA, pT, Grade, pN, CIS, PBC |
| Fradet et al. (2014)  | Canada      | 1990.1–2010.6   | 267/345            | Md67 (IQR59-75)    | Md24.8 (IQR7.69-56.76)      | IRFS              | NA             | 7   | Age, Smoking, PH, Previous abdominal radiotherapy, DUM, CIS, TL, AC |
| Is et al. (2013)      | Japan       | 2005.12–2008.11 | 39/33              | NA                 | R2.6-39.3                   | IRFS              | RE             | 6   | Sex, Age, TS, pT, UC, Grade, CIS, Histology type, AC |
| Kim et al. (2015)     | Korea       | 1992–2012       | 271/100            | Md64.7 (IQR57.7-70.8) | Md50.8 (IQR26.6-103.6)      | OS, CSS, IRFS     | TR             | 8   | Age, ASA, PBC, UC, pT, Grade, LVI, Variant histology of urothelial carcinoma, TL, SM, AC |
| Kitamura et al. (2014) | Japan       | 1995.4–2010.8   | 34/65              | Md69 (R32-88) Md65 (R53-71) | Md70 (R6-192)             | IRFS              | Mixed          | 6   | Grade                        |
| Zou et al. (2014)     | CHN         | 1999.1–2013.2   | 101/21             | Mn63.7 (R35-80)    | Md53 (R3-159)               | IRFS, CSS         | TR             | 7   | Gender, PH, TS, TL, Size, Appearance, Necrosis, pT, Grade, Multifocality, CIS, SM, LVI |
| Yafi et al. (2012)    | Canada      | 1990-/           | 591/46             | Md68 (IQR61-75)    | Md37 (IQR18-68)             | ExRFS, CSS        | NA             | 6   | Age, Race, Gender, TL, pT, Grade, CIS, LVI, pn |
| Walton et al. (2011)  | Multi central | 1987–2008       | 703/70             | Md68 (IQR61-75)    | Md34 (IQR15-65)             | ExRFS, CSS        | NA             | 7   | Age, Gender, Race, PBC, DUM, TL, Grade, pT, pn, LVI, CIS |
| Taweemonkongsap et al. (2008) | Thailand         | 2001.4–2007.1   | 29/31              | Mn66.8 (R39-88) Mn63.8 (R26-79) | Mn27.9 (R3-63) Mn26.4 (R3-72) | UnRFS            | RE             | 5   | pT, Grade                     |
| Metcalfe et al. (2012) | Canada       | 1990–2010       | 403/446            | Mn69.7 (SD10.7)    | Mn26.4 (R7.2-60)            | UnRFS, OS         | NA             | 8   | Region, Age, Symptoms, TL, pT, Grade, CIS, PBC, NeoAC, AC, Salvage chemotherapy, Salvage radiation therapy, SM, Smoking, Previous abdominal RT, pN |
| Kume et al. (2006)    | Japan        | 1996–2003       | 28/13              | Mn65.07 (SD9.46) Mn65.31 (SD10.69) | Mn55.7 (SD29.4) Mn53.4 (SD10.9) | IRFS              | RE             | 6   | Multiple tumors, pT, Grade, OT |
| Koda et al. (2007)    | Japan        | 1995.1–2005.8   | 27/29              | Mn67.4 (SD11.3) Mn71.4 (SD8.2) | Mn46.2 (R1-97) Mn16.4 (R1-57.5) | IRFS              | RE             | 6   | Sex, Side, Age, pT, Grade, OT, AC, PBC |
| Ploussard et al. (2015) | Multicentres | 1989–2012       | 2826/922           | Md70 (IQR60-74)    | Md32.7 (IQR13.6-67.4)       | IRFS, CSS         | NA             | 7   | Age, Sex, Ureter location, Multifocality, LN, DUM, pT, High grade, CIS, AC |
| (continued on next page) |          |                 |                    |                    |                             |                   |                 |     |                             |
| Study                        | Country         | Duration          | N of pts (ONU/LNU) | Age (yrs) (ORNU/LRNU) | Follow up (month) (ONU/LNU) | Outcomes         | Approach of LNU | NOS | Adjusted factors               |
|-----------------------------|-----------------|-------------------|--------------------|-----------------------|----------------------------|------------------|-----------------|-----|-------------------------------|
| Rieken et al. (2014)        | Muticentres     | 1987–2007         | 2042/450           | Md69.2 (IQR62-77)     | Md36                       | ExRFS, OS, CSS  | NA              | 5   | Univariable Cox regression    |
| Fairey et al. (2013)        | Canada          | 1994–2009         | 403/446            | Md70.5               | Md26.4 (IQR7.2-60)         | UnRFS, OS, CSS  | Mixed           | 7   | Age, Sex, AC, pT, pN, Grade, SM |
| Capitanio et al. (2009)     | Muticentres     | 1987-2007         | 979/270            | Mn68.3 (R27-97) Mn70.2 (R36-94) | Md49                       | ExRFS, CSS      | NA              | 7   | Age, pT, pN, Grade, LVI, ECOG PS, pN, PBC, Previous endoscopy, CIS |
| Ariane et al. (2012)        | France          | 1995–2010         | 459/150            | Md69.8 (R60.9-76) Md69.5 (R63-77) | Md27 (R10-48)              | UnRFS, CSS, TR  | 6               |    | Gender, Age, ASA physical status, TL, pT, Grade, pN, LVI           |
| Kobayashi et al. (2012)     | Japan           | 2005.1–2009.4     | 151/137            | Md71.4 (R32-89)       | Md20.2 (R3.0-61.6)         | IRFS RE         | 6               |    | TL, Time of ligation of the ureter, UC.                           |
| Terekawa et al. (2008)      | Japan           | 2000.1–2005.12    | 111/66             | Mn71.3 (SD9.6) Mn87.7 (SD9.5) | Mn31 (R12.0-80.5)         | IRFS RE         | 7               |    | Age, TL, Multifocality, OT, DUM, pT, Grade, pN, LVI, SM            |
| Ishikawa et al. (2010)      | Japan           | 1990–2005         | 165/43             | Md70 (R39-90)         | Md8 (R2-105)               | IRFS, CSS RE    | 5               |    | Univariable Cox regression  |
| Xylinas et al. (2013)       | France          | 1995–2009         | 350/132            | Mn69.2 (IQR60-76) Mn39.5 (IQR25-60) | IRFS NA                   | IRFS NA        | 6               |    | Age, Gender, TL, Multifocality, PBC, Endoscopic management, pT, Grade, CIS, LVI, pN |

Notes. yrs; years; N of pts, number of patients; Mn, mean; Md, median; R, range; IQR, interquartile range; NA, not applicable; IRFS, intravesical recurrence free survival; ExRFS, extravesical recurrence free survival; UnRFS, unspecified recurrence free survival; OS, overall survival; CSS, cancer specific survival; RE, retroperitoneal; TR, transperitoneal; NOS, Newcastle-Ottawa Scale; pT, pT stage; pN, pN stage; TL, tumor location; PH, previous hydronephrosis; DUM, distal ureter management; TS, tumor side; UC, urinary cytology; SM, surgical margin; PBC, previous bladder cancer; ASA, American Society of Anesthesiology physical status; AC, adjuvant chemotherapy; OT, operation time; CIS, carcinoma in situ; LVI, lymphovascular invasion; ECOG PS, Eastern Cooperative Oncology Group performance score.
studies including LNU (n = 1,126) and ONU (n = 1,403) (Ariane et al., 2012; Fairey et al., 2013; Favaretto et al., 2010; Metcalfe et al., 2012; Taweemonkongsap et al., 2008) reported the UnRFS. The pooled analysis of the available HRs showed that the different surgical procedures were not significantly correlated with disease recurrence (HR 1.10, 95% CI [0.93–1.28]; P = 0.337, I² = 12.0%; Fig. 4).

**Mortality**

Among the four studies that provided the HRs of OS, there were 1,442 LNU patients and 3,119 ONU patients (Fairey et al., 2013; Kim et al., 2015; Metcalfe et al., 2012; Rieken et al., 2014). There was significant heterogeneity (P = 0.091, I² = 53.7%; Fig. 5), and a random model was applied. The model showed that neither LNU nor ONU significantly increased the risk in the overall survival (HR 0.91, 95% CI [0.66–1.17]; Fig. 5). The CSS was described in ten articles, in which 2,518 patients were treated by LNU and 8,342 patients were treated by ONU (Ariane et al., 2012; Capitanio et al., 2009; Fairey et al., 2013; Ishikawa et al., 2010; Kim et al., 2015; Ploussard et al., 2015; Rieken et al., 2014; Walton et al., 2011; Yafi et al., 2012; Zou et al., 2014). The pooled results indicated that LNU could improve the cancer specific survival (HR 0.79, 95% CI [0.68–0.91]; P = 0.186, I² = 28.1%; Fig. 6).

**Subgroup analysis and multivariable meta-regression for IRFS**

In subgroup analysis for the effect of different approaches of LNU on IRFS, no difference were seen among people with retroperitoneal laparoscopy (HR 1.04, 95% CI [0.77–1.32];
Figure 2  Forest plot of Intravesical Recurrence Free Survival (IRFS) hazard ratio.

Figure 3  Forest plot of Extravesical Recurrence Free Survival (ExRFS) hazard ratio.
Figure 4 Forest plot of Unspecified Recurrence Free Survival (UnRFS) hazard ratio.

Figure 5 Forest plot of Overall Survival (OS) hazard ratio.

\( P = 0.598, I^2 = 0.0\% \); Fig. 7) and transperitoneal laparoscopy (HR 0.81, 95\% CI [0.48–1.13]; \( P = 0.548, I^2 = 0.0\% \); Fig. 7). The subgroup of five studies with sample sizes of LNU more than 100 had a combined HR of 1.31 (95\% CI[0.92–1.70]) with significant heterogeneity (\( P = 0.011, I^2 = 69.5\% \); Fig. 8), while the subgroup of eight studies with sample sizes of less than 100 had a combined HR of 0.97 (95\% CI [0.67–1.16]) without
significant heterogeneity ($P = 0.919, I^2 = 0.0\%$; Fig. 8). Multivariable meta-regression showed no particular influence of different approaches of LNU ($P = 0.431$), sample size ($P = 0.899$) and publication year ($P = 0.729$) on the results.

**Publication bias and sensitivity analysis**

The publication bias detection was conducted by Egger’s asymmetric test and only for IRFS outcomes. The $P$ value of the linear regression was 0.515, and no significant publication bias was observed (Fig. S1). We also performed sensitivity analyses of IRFS and CSS, and no significance change was observed (Figs. S2 and S3).

**DISCUSSION**

Recently, some retrospective studies have paid attention to the predictors of disease recurrence in patients with UTUC after RNU; these studies found that CIS, previous bladder cancer, laparoscopic surgery and distal ureteral management were risk factors for disease recurrence (Xylinas et al., 2014). A systemic review concluded that a laparoscopic approach significantly increased the risk of intravesical recurrence (Seisen et al., 2015). However, there are many studies that suggested that laparoscopic surgery could provide equivalent oncologic control compared with open surgery (Favaretto et al., 2010; Ishikawa et al., 2010). Therefore, we conducted this meta-analysis enrolling twenty-one retrospective studies that contained various oncologic outcomes to assess whether LNU would show a tendency toward a poor prognosis for UTUC patients.
Open nephroureterectomy, the traditional surgical approach that could support a durable tumor control, has long been accepted as the standard surgical treatment for UTUC, especially for high-risk UTUC (Roupret et al., 2015). As a viable minimally invasive therapy, LNU was developed in an effort to reduce the morbidity of the surgical management and had advantages of lesser blood loss, shorter hospital stay and oncologic outcomes compared with ONU. With a median follow-up of 45 months of 1,261 UTUC patients who underwent ONU \( (n = 926) \) or LNU \( (n = 335) \), Xylinas et al., 2014 showed that the laparoscopic approach was associated with a higher risk of intravesical recurrence compared with open surgery \( (HR = 1.5, 95\% CI [1.17–1.93]) \). It was suggested that the high pressure pneumoperitoneum during LNU might trigger tumor dissemination and could result in a higher rate of recurrence, which contributed to the debate on oncologic outcomes of UTUC patients after laparoscopic procedures. Few cases of laparoscopic port-side seeding were reported in some literature in the early years, and Roupret et al. (2015) proposed that ensuring a closed system during laparoscopic surgery and avoiding direct contact between instruments and tumors might favor tumor control. In 150 laparoscopic surgeries, (Ariane et al., 2012) reported three cases of laparoscopic port-side seeding occurred in early experiences. After the widespread use of laparoscopic bags for specimen extraction, no cases happened. Our pooled results demonstrated that LNU could provide equivalent tumor control of intravesical recurrence and unspecified RFS compared to ONU. However, the majority of the enrolled studies reported negative control for ONU in extravesical recurrence. Our results showed that ONU was an independent risk for ExRFS.
However, considering that there were only four articles enrolled, whether open surgery increased the risk of extravesical recurrence still needs further exploration. Our analysis based on the current evidence did not support the view that laparoscopic surgery increased the risk of disease recurrence of patients with UTUC after nephroureterectomy.

Regarding survival outcomes, our data demonstrated that LNU was comparable to ONU in overall survival, and superior in cancer specific survival. In the first randomized prospective study, the cancer specific survival rate and the metastasis free survival rate were significantly different between the LNU and ONU groups, which favored ONU after matching for pT3 and high-grade tumors (Simone et al., 2009). In the 2015 EAU guidelines, invasive or large (T3/T4 and/or N+/M+) tumors were deemed as contraindications for a laparoscopic approach (Roupret et al., 2015). Recently, Kim et al. (2015) retrospectively analyzed the data of 371 UTUC patients who underwent ONU (n = 271) or LNU (n = 100); the results indicated that LNU had worse five-year OS and CSS rates than the ONU group only in locally advanced disease (pT3/T4) after stratifying by pathological stages. However, this conclusion was not identified in Arian’s research in tumors of the pathological stages of pT3/T4 (Ariane et al., 2012). A recent study including 749 muscle-invasive UTUC patients who underwent ONU (n = 527) or LNU (n = 222) also indicated that the oncological outcomes of LNU were not inferior to the outcomes of ONU (Miyazaki et al., 2016).
Although our analysis did not include a subgroup analysis of survival outcomes (OS and CSS) in locally advanced UTUC patients because of a lack more relevant survival data, our results might be reliable because the majority of our data were extracted from multivariate analyses, the majority of which adjusted for the effect of tumor stages and grades. Furthermore, a previous systematic review also showed that no significant differences in the stages of pT3/T4 or pathologic grades were observed in the LNU group compared with the ONU group (Ni et al., 2012).

Previous systematic reviews on the oncologic outcomes comparing LNU with ONU were published in 2012 (Ni et al., 2012; Rai et al., 2012). These cumulative analyses conducted by using non-time to event data suggested that LNU could offer reliable perioperative safety and comparable oncologic efficacy compared to ONU. The meta-analysis conducted by Ni et al. indicated that LNU could improve the 5-yr CSS and decrease the rates of the overall recurrence and bladder recurrence. Recently, Seisen et al. (2015) observed that LNU was a significant predictor of the IRFS in their meta-analysis enrolling in six studies (HR 1.62; 95% CI [1.18–2.22]). After enrolling more available HRs extracted from multivariate or univariable Cox regression, our results showed there was no significant difference in IRFS between LNU and ONU management, different from the studies of Ni et al. and Seisen et al. We thought the conclusion that LNU could improve the CSS should be interpreted cautiously, although this conclusion was consistent with the previous opinion of Ni et al.

Several limitations must be acknowledged in our meta-analysis. First, this meta-analysis was based on retrospective studies. Although all of these studies were of high quality (>5 stars) according to the modified Newcastle-Ottawa Scale, the intrinsic bias of cohort studies existed. Next, the covariates controlled in the Cox regression analysis were different, which might introduce bias into our analysis. Finally, the time interval of the studies enrolled was more than 20 years. During this period, improvements in surgical techniques and medical materials should be considered. Additionally, these analyses did not include hand assisted laparoscopic nephroureterectomy because its relevant HR by Cox regression analysis for oncologic outcomes was reported in few literatures, and it is frequently deemed as an inferior approach compared with LNU or ONU in terms of the recurrence free survival and intravesical recurrence free survival rates (Kitamura et al., 2014). Given the low incidence of UTUC, high-quality level data were so scarce that our results should be interpreted cautiously. The oncological outcomes of LNU and ONU should be verified by prospective randomized controlled trials, especially for locally advanced disease.

**CONCLUSION**

Based on our meta-analysis of the current evidence, LNU could provide equivalent prognostic effects for upper tract urothelial carcinoma as ONU, and LNU had better results in the ExRFS and CSS. However, considering all eligible studies with the intrinsic bias of retrospective study design, the results should be interpreted with caution, and prospective randomized controlled trials are still needed.
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was founded by Science and Technology Board of Chengguan District, Lanzhou (2015 CGKJ217). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
Science and Technology Board of Chengguan District, Lanzhou: 2015 CGKJ217.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
• Su Zhang conceived and designed the experiments, performed the experiments, analyzed the data, contributed reagents/materials/analysis tools, wrote the paper.
• You Luo conceived and designed the experiments, performed the experiments, contributed reagents/materials/analysis tools.
• Cheng Wang analyzed the data, contributed reagents/materials/analysis tools, prepared figures and/or tables.
• Sheng-Jun Fu prepared figures and/or tables.
• Li Yang reviewed drafts of the paper.

Data Availability
The following information was supplied regarding data availability:
The raw data has been supplied as Data S1.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.2063#supplemental-information.

REFERENCES

Ariane MM, Colin P, Ouzzane A, Pignot G, Audouin M, Cornu JN, Albouy B, Guilhotreau J, Neuzillet Y, Crouzet S, Hurel S, Arroua F, Bigot P, Marchand C, Fais PO, De la Taille A, Saint F, Ravier E, Matte A, Guy L, Bruyere F, Roupnet M. 2012. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large french multicenter collaborative study. Annals of Surgical Oncology 19:301–308 DOI 10.1245/s10434-011-1841-x.

Capitanio U, Shariat SF, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernandez MI, Strobel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F,
Wood CG, Margulis V, Karakiewicz PI. 2009. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. *European Urology* 56:1–9 DOI 10.1016/j.eururo.2009.03.072.

Clayman RV, Kavoussi LR, Figenshau RS, Chandhoke PS, Albala DM. 1991. Laparoscopic nephroureterectomy: initial clinical case report. *Journal of Laparoendoscopic Surgery* 1:343–349 DOI 10.1089/lps.1991.1.343.

Egger M, Davey Smith G, Schneider M, Minder C. 1997. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 315:629–634 DOI 10.1136/bmj.315.7109.629.

Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, Cagiannos I, Lacombe L, Fradet Y, Jacobsen NE. 2013. Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. *BJU International* 112:791–797 DOI 10.1111/j.1464-410X.2012.11474.x.

Favaretto RL, Shariat SF, Chade DC, Godoy G, Kaag M, Cronin AM, Bochner BH, Coleman J, Dalbagni G. 2010. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? *European Urology* 58:645–651 DOI 10.1016/j.eururo.2010.08.005.

Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, Sheyegan B, Drachenberg D, Cagiannos I, Lacombe L. 2014. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. *Urologic Oncology* 32:839–845 DOI 10.1016/j.urolonc.2014.04.006.

Ishikawa S, Abe T, Shinohara N, Harabayashi T, Sazawa A, Maruyama S, Kubota K, Matsuno Y, Osawa T, Shino Y, Kumagai A, Togashi M, Matsuda H, Mori T, Nonomura K. 2010. Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract. *Journal of Urology* 184:883–887 DOI 10.1016/j.juro.2010.05.027.

Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y. 2013. Prospective randomized phase ii trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. *Journal of Clinical Oncology* 31:1422–1427 DOI 10.1200/JCO.2012.45.2128.

Kim HS, Ku JH, Jeong CW, Kwak C, Kim HH. 2015. Laparoscopic radical nephroureterectomy is associated with worse survival outcomes than open radical nephroureterectomy in patients with locally advanced upper tract urothelial carcinoma. *World Journal of Urology* Epub ahead of print Oct 23 2015 DOI 10.1007/s00345-015-1712-3.
Kitamura H, Maeda T, Tanaka T, Fukuta F, Kobayashi K, Nishiyama N, Takahashi S, Masumori N. 2014. Comparison of laparoscopic, hand-assisted, and open surgical nephroureterectomy. *JSLS* 18:288–293 DOI 10.4293/108680813X13794522666842.

Kobayashi Y, Saika T, Miyaji Y, Saegusa M, Arata R, Akebi N, Takenaka T, Manabe D, Nasu Y, Kumon H. 2012. Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. *World Journal of Urology* 30:271–275 DOI 10.1007/s00345-011-0731-y.

Koda S, Mita K, Shigeta M, Usui T. 2007. Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. *Japanese Journal of Clinical Oncology* 37:296–301 DOI 10.1093/jjco/hym016.

Kume H, Teramoto S, Tomita K, Nishimatsu H, Takahashi S, Takeuchi T, Ota N, Kitamura T. 2006. Bladder recurrence of upper urinary tract cancer after laparoscopic surgery. *Journal of Surgical Oncology* 93:318–322 DOI 10.1002/jso.20459.

Metcalfe M, Kassouf W, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey A, Jacobson NE, Drachenberg D, Cagiannos I, So A, Black P. 2012. Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. *Canadian Urological Association Journal* 6:455–462 DOI 10.5489/cuaj.12146.

Miyazaki J, Nishiyama H, Fujimoto H, Ohyama C, Koie T, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T. 2016. Laparoscopic versus open nephroureterectomy in muscle-invasive upper tract urothelial carcinoma: subanalysis of the multi-institutional national database of the Japanese Urological Association. *Journal of Endourology* 30:520–525 DOI 10.1089/end.2015.0757.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. 2010. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *International Journal of Surgery* 8:336–341 DOI 10.1016/j.ijsu.2010.02.007.

Ni S, Tao W, Chen Q, Liu L, Jiang H, Hu H, Han R, Wang C. 2012. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. *European Urology* 61:1142–1153 DOI 10.1016/j.eururo.2012.02.019.

Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Roupret M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, Shariat SF, Kassouf W. 2015. Conditional survival after radical nephroureterectomy for upper tract carcinoma. *European Urology* 67:803–812 DOI 10.1016/j.eururo.2014.08.003.

Rai BP, Shelley M, Coles B, Somani B, Nabi G. 2012. Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. *BJU International* 110:1426–1435 DOI 10.1111/j.1464-410X.2012.11341.x.

Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz
Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper-tract urothelial carcinoma. European Journal of Surgical Oncology 40:113–120 DOI 10.1016/j.ejso.2013.09.016.

European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. European Urology 68:868–879 DOI 10.1016/j.eururo.2015.06.044.

A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. European Urology 67:1122–1133 DOI 10.1016/j.eururo.2014.11.035.

Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. European Urology 56:520–526 DOI 10.1016/j.eururo.2009.06.013.

Outcomes of surgical treatment for upper urinary tract transitional cell carcinoma: comparison of retroperitoneoscopic and open nephroureterectomy. World Journal of Surgical Oncology 6:3 DOI 10.1186/1477-7819-6-3.

Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. Urology 71:123–127 DOI 10.1016/j.urology.2007.08.054.

Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU International 108:406–412 DOI 10.1111/j.1464-410X.2010.09826.x.

The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital. Available at http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp/ (accessed 10 January 2016).

Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World Journal of Urology 31:61–68 DOI 10.1007/s00345-012-0957-3.
Xylinas E, Kluth L, Passoni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Roupret M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, Shariat SF, Collaboration U. 2014. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. European Urology 65:650–658 DOI 10.1016/j.eururo.2013.09.003.

Yafi FA, Novara G, Shariat SF, Gupta A, Matsumoto K, Walton TJ, Fritsche HM, El-Hakim A, Trischler S, Martinez-Salamanca JI, Seitz C, Ficarra V, Zattoni F, Karakiewicz PI, Kassouf W. 2012. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU International 110:E7–E13 DOI 10.1111/j.1464-410X.2011.10792.x.

Zou L, Zhang L, Zhang H, Jiang H, Ding Q. 2014. Comparison of post-operative intravesical recurrence and oncological outcomes after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma. World Journal of Urology 32:565–570 DOI 10.1007/s00345-013-1160-x.